Viral Peptide Or Viral Protein (see Note 6) Patents (Class 930/220)
  • Patent number: 8541221
    Abstract: Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: September 24, 2013
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Johns Hopkins University
    Inventors: William M. Switzer, Walid Heneine, Thomas M. Folks, Nathan D. Wolfe, Donald S. Burke, Eitel Mpoudi Ngole
  • Patent number: 8513397
    Abstract: Plant viral vectors have great potential in rapid production of proteins, but no simple. Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: August 20, 2013
    Assignee: The Arizona Board of Regents for and on behalf of Arizona State University
    Inventors: Hugh S. Mason, Zhong Huang, Qiang Chen, Charles J. Arntzen, Shuo Yuan, Brooke Hjelm
  • Patent number: 7378234
    Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 27, 2008
    Assignee: Intercell AG
    Inventors: Michael Buschle, Andre Habel, Christoph Klade, Frank Mattner, Alexander Otava, Oresta Vytvytska, Wolfgang Zauner, Sandra Zinke, Helen Kirlappos
  • Patent number: 7037707
    Abstract: The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain with the NS gene of the A/England/1/53 strain. The invention provides influenza viruses and vaccines generated in mammalian cells as well as methods for producing such. The invention further provides an influenza virus master strain and kits for generating reassortant influenza viruses in mammalian cell culture and methods of making and using the master strain.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: May 2, 2006
    Assignee: St. Jude Children's Research Hospital
    Inventors: Robert Gordon Webster, Richard John Webby, Hiroichi Ozaki
  • Patent number: 6943233
    Abstract: Cyclic peptides which comprise, as a constituent chain or chains thereof, one or two amino acid sequences selected from the amino acid sequence Asn-Val-Ser-Glu-Ala-Asp-Asp-Arg-Tyr-Ile and the amino acid sequence Arg-Ser-Gln-Lys-Glu-Gly-Leu-His-Tyr-Thr, and AIDS vaccines containing at least one of the cyclic peptides as an active ingredient. From the in vivo absorption and antibody expression viewpoint, a substituent group is preferably bound to at least one active group selected from among the carboxyl, amino and hydroxyl groups contained in the cyclic peptides. The cyclic peptides can neutralize the second receptors which the HIV-1 virus utiliizes in the infection of humans therewith.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: September 13, 2005
    Assignee: Nissui Pharmaceutical Co., Ltd.
    Inventor: Shozo Shoji
  • Patent number: 6406705
    Abstract: The present invention relates generally to adjuvants, and in particular to methods and products utilizing a synergistic combination of immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) and a non-nucleic acid adjuvant. Such combinations of adjuvants may be used with an antigen or alone. The present invention also relates to methods and products utilizing immunostimulatory oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) for induction of cellular immunity in infants.
    Type: Grant
    Filed: June 3, 1999
    Date of Patent: June 18, 2002
    Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbH, Ottawa Health Research Institute
    Inventors: Heather L. Davis, Joachim Schorr, Arthur M. Krieg
  • Patent number: 6344314
    Abstract: The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS. 1a and 1b respectively: 76-556 543-864 867-2811 2728-3808 3326-3575 3842-4079 4198-5611 5516-8091 The invention also relates to the use of these fragments as probes for the detection of HPV in tissue cultures.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: February 5, 2002
    Assignee: Institut Pasteur
    Inventors: Stewart Cole, Rolf E. Streeck
  • Publication number: 20010034021
    Abstract: The invention relates to seroreactive regions on proteins E1 and E2 of human papillomavirus (HPV) 16.
    Type: Application
    Filed: January 12, 2001
    Publication date: October 25, 2001
    Applicant: Dade Behring Marburg GmbH
    Inventors: Martin Muller, Lutz Gissmann
  • Patent number: 6297357
    Abstract: The present invention provides peptides of pRb2/p130 or mutants or fragments thereof which inhibit cdk2 kinase activity. Method of inhibiting cdk2 kinase activity in cells with these peptides are also provided.
    Type: Grant
    Filed: August 6, 1998
    Date of Patent: October 2, 2001
    Assignee: Thomas Jefferson University
    Inventor: Antonio Giordano
  • Patent number: 6221577
    Abstract: The invention relates to seroreactive regions on protein E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces compositions for diagnostic purposes which contain peptides with the seroreactive regions.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 24, 2001
    Assignee: Dade Behring Marburg GmbH
    Inventors: Martin Müller, Lutz Gissmann
  • Patent number: 6218364
    Abstract: Peptide derivatives which are antagonists of neurokinin A. The derivatives have a modified peptide bond having a reduced amide and a fluorinated alkyl attached to the nitrogen atom of the modified peptide bond. For example, Asp-Ser-Phe-Val-Gly-Leu&PSgr;[CH2N(CH2CF3)]Leu(NH2).
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: April 17, 2001
    Inventors: Scott L. Harbeson, James R. McCarthy
  • Patent number: 6171592
    Abstract: Equine rhinovirus 1 (ERhV1) is a respiratory pathogen of horses which has an uncertain taxonomic status. The nucleotide sequence of the ERhV1 genome and amino acid sequence have been substantially determined (FIG. 2). The predicted polyprotein was encoded by 6,741 nucleotides and possessed a typical picornavirus proteolytic cleavage pattern, including a leader polypeptide. The genomic structure and predicted amino acid sequence of ERhV1 were more similar to those of foot-and-mouth disease viruses (FMDV), the only members of the aphthovirus genus, than other picornaviruses. Nucleotide sequences coding for the complete polyprotein, the polymerase, and VP1 were analyzed separately. The phylogenetic trees confirmed that ERhV1 was more closely related to aphthoviruses than to other picornaviruses. Virion proteins and virus-like particles are described and probes, primers, antigens, vectors, diagnostics and tests developed.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: January 9, 2001
    Assignee: The University of Melbourne
    Inventors: Michael J. Studdert, Brendan S. Crabb, Li Feng
  • Patent number: 6120989
    Abstract: Diagnostically relevant polypeptides and fusion proteins comprising an amino acid sequence which originates from cytomegalovirus and corresponds to a region of the major DNA-binding protein or of the C-terminal region of the tegument protein pp150 fused with at least one further fragment from another antigenic protein of cytomegalovirus are disclosed. The major DNA-binding protein is encoded by the reading frame UL57. The poly-peptides and fusion proteins according to the invention can be used in an advantageous manner in diagnostic tests and methods for the detection of IgM antibodies against cytomegalovirus.
    Type: Grant
    Filed: July 25, 1995
    Date of Patent: September 19, 2000
    Assignee: Biotest AG
    Inventors: Rolf Vornhagen, Walter Hinderer, Hans-H. Sonneborn, Bodo Plachter, Gerhard Jahn
  • Patent number: 6010704
    Abstract: The present invention provides papillomavirus DNA, and more particularly DNA probes derived from papillomavirus. The present invention also provides procedures for the use of DNA derived from papillomavirus in the in vitro diagnosis of papillomavirus infections.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 4, 2000
    Assignee: Institut Pasteur and Institut National de la Sante et de la Recherche Medicale
    Inventors: Carol Ann Komly, Odile Croissant, Francoise Breitburd
  • Patent number: 6010700
    Abstract: The invention involves polypeptides which correspond to amino acid sequences of protein p57 or protein p9.5 of Borna disease virus. These polypeptides, as well as DNA and RNA fragments are used in test kits and vaccines.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: January 4, 2000
    Inventor: Jurgen A. Richt
  • Patent number: 5989548
    Abstract: Pharmaceutical compositions comprising an antigenic amount of peptides derived from the L1 and L2 OFR's of human papillomavirus type 16 coupled to a carrier or in multimer form.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: November 23, 1999
    Assignee: Euro-Diagnostica AB
    Inventor: Joakim Dillner
  • Patent number: 5990276
    Abstract: An inhibitor of the HCV NS3 protease. The inhibitor is a subsequence of a substrate of the NS3 protease or a subsequence of the NS4A cofactor. Another inhibitor of the present invention contains a subsequence of a substrate linked to a subsequences of the NS4A cofactor. In another embodiment the inhibitor is a bivalent inhibitor comprised of a subsequence, a mutated subsequence or a mutated full-length of a substrate of the NS3 protease linked to a subsequence, a mutated subsequence or a mutated full-length suquence of the HCV NS4A cofactor.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: November 23, 1999
    Assignee: Schering Corporation
    Inventors: Rumin Zhang, Philip W. Mui, Patricia C. Weber
  • Patent number: 5989804
    Abstract: E6-BP polypeptides, nucleic acids encoding E6-BP polypeptides, and uses thereof.
    Type: Grant
    Filed: November 14, 1995
    Date of Patent: November 23, 1999
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, Jason J. Chen
  • Patent number: 5871740
    Abstract: A protein designated p35 binds to a number of the chemotaxis-stimulating cytokines known as chemokines. p35 may be used to treat conditions that are mediated by chemokines, such as inflammation. p35 is a secreted protein that can be purified from the culture supernatant of cells infected with certain viruses, or produced using recombinant DNA techniques. Isolated DNA sequences encoding p35 are provided, along with expression vectors comprising the p35 DNA, and purified p35 protein.
    Type: Grant
    Filed: September 26, 1996
    Date of Patent: February 16, 1999
    Assignee: Immunex Corporation
    Inventor: Craig A. Smith
  • Patent number: 5788969
    Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 4, 1998
    Assignee: The Scripps Research Institute
    Inventor: Francis V. Chisari
  • Patent number: 5707629
    Abstract: The present invention is directed to a gene encoding an envelope glycoprotein of equine herpesvirus type 1 (EHV-1), the glycoprotein D (gD) gene, its gene product and antibodies directed against gD polypeptides. The envelope glycoproteins of herpesvirus are major targets of the immune response to herpesviral infection. Hence, an important aspect of this invention is directed towards a vaccine against EHV-1 and treatment of EHV-1 infection by anti-EHV-gD antibodies or antisera.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: January 13, 1998
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Dennis J. O'Callaghan
  • Patent number: 5688511
    Abstract: Compositions including a polypeptide or nucleic acid sequence encoding a polypeptide that binds TAR DNA (particularly the region -18 to +28 of HIV-LTR DNA) and that does not bind to TAR RNA (particularly the region +1 to +80 of the TAR RNA) are disclosed. The cellular binding protein TDP-43 including the polypeptide has an estimated molecular weight of between about 40 kD and 46 kD as determined by SDS polyacrylamide gel electrophoresis. Fusion proteins that include the entire cellular binding protein TDP-43 or fragments thereof are also described. The cellular binding protein, peptide fragments and nucleic acid sequences encoding them, repress HIV gene expression. Methods for preparing the cellular binding protein from cells as recombinant proteins with recombinant host cells are also disclosed. Antibodies to the TDP-43 cellular binding protein are also described. The isolated nucleic acid sequences of the protein and its fragments are described in the construction of retroviral vectors.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: November 18, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard B. Gaynor, S.-H. Iqnatius Ou, Foon Kin Wu
  • Patent number: 5672684
    Abstract: An isolated gene encoding all or part of the VP7 protein of human rotavirus serotype 4 is claimed. Also claimed in a DNA transfer vector which contains the gene or a portion or sub-unit and a host cell contg. the DNA transfer vector.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: September 30, 1997
    Assignees: The University of Sydney, The University of Melbourne
    Inventors: Michael Leigh Dyall-Smith, Chris Hum, Ian Hamilton Holmes, Michael Anthony Johnson, Peter Richard Reeves
  • Patent number: 5622703
    Abstract: The invention relates to peptides representing CTL epitopes from the HTLV-I envelope protein. The invention further relates to compositions, comprising the peptides, for priming a T-cell response in a subject. Furthermore, methods for priming a T-cell response by administration of the compositions to a subject and methods for evaluating the T-cell function of a patient are described.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: April 22, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jay A. Berzofsky, Akihiko Kurata
  • Patent number: 5601973
    Abstract: The invention relates to seroreactive regions on proteins E1 and E2 of human papillomavirus (HPV) 16.The application also relates to a vaccine which contains such peptides which contain the seroreactive regions.The invention likewise embraces compositions for diagnostic purposes which contain peptides with the seroreactive regions.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: February 11, 1997
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Martin M uller, Lutz Gissmann
  • Patent number: 5595739
    Abstract: Mutant Hepatitis B Virus (HBV) nucleic acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HBV nucleic acid sequences, HBV immunogenic particles, and a method for producing antibodies to HBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HBV nucleic acid sequences.
    Type: Grant
    Filed: May 7, 1993
    Date of Patent: January 21, 1997
    Assignee: Abbott Laboratories
    Inventors: William F. Carman, Richard H. Decker, Lesley Wallace, Larry T. Mimms, Larry R. Solomon
  • Patent number: 5595884
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. This invention also relates to DNA sequences and recombinant DNA molecules encoding such repressors, unicellular hosts transformed with such DNA molecules, and processes for producing and using such repressors. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication.
    Type: Grant
    Filed: September 24, 1993
    Date of Patent: January 21, 1997
    Assignees: Biogen Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum
  • Patent number: 5574132
    Abstract: This invention relates to novel peptides and mixtures thereof useful for detecting HCV infections. These peptides are also useful as active ingredients in vaccines against HCV infection.
    Type: Grant
    Filed: April 5, 1991
    Date of Patent: November 12, 1996
    Assignee: BioChem Immunosystems Inc.
    Inventor: Martial Lacroix
  • Patent number: 5532340
    Abstract: The invention provides a tumor suppressor protein of the retinoblastoma family (pRb2) which binds to the E1A transforming domain and to DNA encoding for the pRb2 protein.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: July 2, 1996
    Assignee: Temple University of The Commonwealth System of Higher Education
    Inventor: Antonio Giordano
  • Patent number: 5397695
    Abstract: Useful materials for diagnostic tests, affinity chromatography, enzymatic reactions and immunoassays are prepared by covalently attaching reactive compounds containing reactive amino or sulfhydryl groups to polymeric particles having pendant carboxyl groups on the outer surfaces. Such reactive compounds include biologically reactive species, such as enzymes, polypeptides and proteins. This attachment is carried out using carbamoylonium compounds which react with the carboxyl groups to form intermediate reactive groups which then react with the amino or sulfhydryl groups to form a covalent linkage between particle and reactive compound. A kit comprises polymeric particles having carboxyl groups on the outer surfaces, and a carbamoylonium compound.
    Type: Grant
    Filed: June 29, 1989
    Date of Patent: March 14, 1995
    Assignee: Eastman Kodak Company
    Inventors: Richard C. Sutton, Susan J. Danielson, Pranab Bagchi, Patricia M. Scensny
  • Patent number: 5378805
    Abstract: The present invention relates a peptide having specific immunoreactivity to antibodies to HTLV-I, HTLV-II, or combinations thereof comprising a peptide selected from the group consisting of:Env-1 (HTLV-I; a.a 191-214)LPHSNLDHILEPSIPWKSKLLTLV,Env-2 (HTLV-II; a.a 187-210)VHDSDLEHVLTPSTSWTTKILKFI,Env-5 (HTLV-I; a.a 242-257)SPNVSVPSSSSTPLLY,Gag-1a (HTLV-I; a.a 102-117)PPSSPTHDPPDSDPQI,Pol-3 (HTLV-I; a.a 487-502)KQILSQRSFPLPPPHK, andanalogues thereof, wherein the amino acids in the sequence may be substituted as long as the immunoreactivity to antibodies to HTLV-I or HTLV-II derived from the three dimensional conformation of the sequences is substantially preserved.The invention is further directed to an immunoassay method for the detection of antibodies to HTLV-I, HTLV-II or a combination thereof, a test kit for the detection of said antibodies, a peptide composition containing said peptides and a vaccine.
    Type: Grant
    Filed: August 29, 1990
    Date of Patent: January 3, 1995
    Assignee: United States of America
    Inventor: Renu B. Lal
  • Patent number: 5359039
    Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to Tumor Necrosis Factor, thereby functioning as Tumor Necrosis Factor antagonists. Also disclosed are processes for preparing isolated viral protein cytokine antagonists.
    Type: Grant
    Filed: July 9, 1993
    Date of Patent: October 25, 1994
    Assignee: Immunex Corporation
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • Patent number: 5350671
    Abstract: Immunoassays for the detection of antibodies to HCV are provided which employ "C" domain antigens. Immunoassay kits comprising such antigens are also provided.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: September 27, 1994
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo
  • Patent number: 5321124
    Abstract: A gene and gene product that regulates the expression of the capsidal envelope genes of HTLV-III/LAV and that can be used to regulate the expression of heterologous (non-viral) genes as well is disclosed. This art gene consists of two exons and can be used in creating nucleotide segments, vectors and cell lines. A new method for screening for compounds that inhibit the replication of HTLV-III is also described and comprises:(1) transfecting a T-cell line with the HTLV-III art and env genes;(2) thereafter, adding a preselected compound to the transformed cell line in increasing concentrations; and(3) determining whether the compound effects the art function without being toxic to the cell.An additional parameter to use in diagnosis of AIDS disease is also described. The use of the art gene and gene product in AIDS therapy is also disclosed.
    Type: Grant
    Filed: December 18, 1992
    Date of Patent: June 14, 1994
    Assignee: Dana Farber Cancer Institute
    Inventors: William A. Haseltine, Craig A. Rosen, Joseph G. Sodroski, Wei C. Goh
  • Patent number: 5219990
    Abstract: This invention relates to E2 trans-activation repressors which interfere with normal functioning of the native full-length E2 transcriptional activation protein of the papillomavirus. Native full-length E2 trans-activation protein activates transcription of papillomavirus only through binding to DNA, and it binds to DNA only in the form of a pre-formed homodimer--a pair of identical polypeptide subunits held together by non-covalent interactions. The E2 trans-activation repressors of this invention are proteins, polypeptides or other molecules that dimerize with full-length native E2 polypeptides to form inactive heterodimers, thus interfering with the formation of active homodimers comprising full-length native E2 polypeptides, thereby repressing papillomavirus transcription and replication. The E2 trans-activation repressors of this invention are advantageously used in the treatment of papillomavirus infections and their associated diseases.
    Type: Grant
    Filed: January 28, 1991
    Date of Patent: June 15, 1993
    Assignees: Biogen, Inc., New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, James G. Barsoum
  • Patent number: 5198536
    Abstract: The invention relates to a DNA fragment containing at the most 315 pairs of nucleotides coding for a peptide which can be recognized by antibodies acting both against the "C" and "D" particles of the same poliovirus and against the VP-1 structural polypeptide of the capsid of this poliovirus. This peptide contains in particular the following sequence:Asp Asn Pro Ala Ser thr Thr Asn Lys Asp Lys Leu.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: March 30, 1993
    Assignee: Institut Pasteur
    Inventors: Marc Girard, Sylvie Van Der Werf
  • Patent number: 5175098
    Abstract: Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising a portion of the gag region of LAV. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagonstic assays which detect the presence of LAV antigens or antibodies immunologically reactive with LAV. Further, the proteins produced by the method disclosed may be used as a vaccine against infection by the caustive virus for acquired immune deficiency syndrome.
    Type: Grant
    Filed: July 28, 1989
    Date of Patent: December 29, 1992
    Assignee: Genetic Systems Corporation
    Inventors: Susan M. Watanabe, Wesley L. Cosand, Susan McArdle, Pamela J. Ward
  • Patent number: 5175097
    Abstract: Immunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising pGAG-1. Preferred signals for expression are selected from an inducible and/or suppressible operon, such as the trp operon. The gag proteins are isolated from the bacterial host and are utilized in diagnostic assays which detect the presence of LAV/HTLV-III antigens or antibodies immunologically reactive with LAV/HTLV-III. Further, the proteins produced by the method disclosed may be used as a vaccine against infection by the causative virus for acquired immune deficiency syndrome.
    Type: Grant
    Filed: September 10, 1990
    Date of Patent: December 29, 1992
    Assignee: Genetic Systems Corporation
    Inventors: Susan M. Watanabe, Wesley L. Cosand, Susan McArdle, Pamela J. Ward
  • Patent number: 5157110
    Abstract: A substantially pure, synthetic protein possessing anti-complement property and a DNA sequence encoding said protein are described.
    Type: Grant
    Filed: August 20, 1988
    Date of Patent: October 20, 1992
    Assignee: The Government of the United States of America
    Inventors: Girish Kotwal, Bernard Moss